Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.02
-1.9%
$3.31
$2.56
$7.73
$400.72M0.185.60 million shs3.58 million shs
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$41.91
-4.9%
$54.35
$41.55
$160.65
$1.27B0.831.18 million shs1.14 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,014.93
+2.5%
$939.87
$623.78
$1,133.95
$932.20B0.483.58 million shs3.48 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$47.13
+0.3%
$39.42
$35.12
$81.44
$209.86B0.7718.74 million shs9.99 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.72
+1.3%
$33.40
$22.96
$43.15
$3.64B0.722.33 million shs2.27 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-0.32%+0.65%-4.94%-33.48%-48.75%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
+1.68%-8.61%-18.40%-35.64%-71.84%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+2.51%+0.11%+5.35%-2.50%+31.09%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.36%+4.67%+25.18%-3.71%-30.63%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-1.26%+0.03%-8.58%+9.70%+10.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$3.02
-1.9%
$3.31
$2.56
$7.73
$400.72M0.185.60 million shs3.58 million shs
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$41.91
-4.9%
$54.35
$41.55
$160.65
$1.27B0.831.18 million shs1.14 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,014.93
+2.5%
$939.87
$623.78
$1,133.95
$932.20B0.483.58 million shs3.48 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$47.13
+0.3%
$39.42
$35.12
$81.44
$209.86B0.7718.74 million shs9.99 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$31.72
+1.3%
$33.40
$22.96
$43.15
$3.64B0.722.33 million shs2.27 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
-0.32%+0.65%-4.94%-33.48%-48.75%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
+1.68%-8.61%-18.40%-35.64%-71.84%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+2.51%+0.11%+5.35%-2.50%+31.09%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.36%+4.67%+25.18%-3.71%-30.63%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-1.26%+0.03%-8.58%+9.70%+10.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.50
Moderate Buy$18.00496.03% Upside
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
2.15
Hold$85.00102.81% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,218.3320.04% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5639.12% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.85
Moderate Buy$95.50201.07% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, VKTX, ALT, and INSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingNeutral
5/7/2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Reiterated RatingMarket Perform
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/6/2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
DowngradeSell (D+)Sell (D)
5/5/2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Lower Price TargetSector Perform$56.00 ➝ $45.00
5/5/2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Set Price Target$55.00
5/5/2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
DowngradeOverweightNeutral$85.00 ➝ $55.00
5/5/2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Lower Price TargetNeutral$67.00 ➝ $54.00
5/5/2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Lower Price TargetBuy$70.00 ➝ $65.00
5/5/2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Lower Price TargetHold$64.00 ➝ $50.00
5/5/2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
Lower Price TargetEqual Weight$70.00 ➝ $56.00
(Data available from 5/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$40K9,822.55N/AN/A$1.99 per share1.52
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$911.98M1.32$2.72 per share15.39$27.50 per share1.52
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B14.66$25.77 per share39.38$33.13 per share30.63
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.50$4.70 per share10.03$7.12 per share6.62
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$4.32 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.09M-$1.01N/AN/AN/A-214,860.98%-49.35%-41.65%5/13/2026 (Estimated)
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
$145.42M$4.499.3327.574.5514.33%10.35%8.81%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1536.0522.931.0834.98%105.77%23.76%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2611.0613.704.1937.23%63.31%22.19%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)

Latest LLY, NVO, VKTX, ALT, and INSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
5/4/2026Q1 2026
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
-$0.2753$0.10+$0.3753-$0.39$200.04 million$204.58 million
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/29/2026Q1 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.01-$1.37-$0.36-$1.37N/AN/A
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
3/5/2026Q4 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.68%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.71%+21.74%41.08%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest LLY, NVO, VKTX, ALT, and INSP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.72%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
0.15
18.55
18.55
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
N/A
6.34
4.48
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
5.72
5.72

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
94.91%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
50130.10 million128.02 millionOptionable
Inspire Medical Systems, Inc. stock logo
INSP
Inspire Medical Systems
1,33328.81 million28.18 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20116.11 million109.95 millionOptionable

Recent News About These Companies

LGND: 1Q:26 Results Highlight Breadth of Portfolio
HC Wainwright Brokers Decrease Earnings Estimates for VKTX
VKTX Q1 Earnings Miss on Higher Phase 3 Development Costs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$3.02 -0.06 (-1.95%)
Closing price 04:00 PM Eastern
Extended Trading
$3.01 -0.01 (-0.33%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Inspire Medical Systems stock logo

Inspire Medical Systems NYSE:INSP

$41.91 -2.15 (-4.88%)
Closing price 03:59 PM Eastern
Extended Trading
$42.30 +0.39 (+0.93%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,014.93 +25.06 (+2.53%)
Closing price 03:59 PM Eastern
Extended Trading
$1,014.00 -0.93 (-0.09%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$47.12 +0.13 (+0.27%)
Closing price 03:59 PM Eastern
Extended Trading
$47.15 +0.02 (+0.05%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$31.72 +0.40 (+1.28%)
Closing price 04:00 PM Eastern
Extended Trading
$31.85 +0.13 (+0.41%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.